Clinical Study of Divozilimab in Patients With Systemic Scleroderma
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy
and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult
patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR
2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs
of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. Subjects
will be randomized to divozilimab or placebo group.